(NASDAQ: UBX) Unity Biotechnology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Unity Biotechnology's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast UBX's revenue for 2025 to be $458,107,597, with the lowest UBX revenue forecast at $458,107,597, and the highest UBX revenue forecast at $458,107,597. On average, 1 Wall Street analysts forecast UBX's revenue for 2026 to be $467,340,252, with the lowest UBX revenue forecast at $467,340,252, and the highest UBX revenue forecast at $467,340,252.
In 2027, UBX is forecast to generate $982,690,315 in revenue, with the lowest revenue forecast at $982,690,315 and the highest revenue forecast at $982,690,315.